Suzhou Highfine Biotech Co (SZSE:301393) Cash And Cash Equivalents : ¥551.5 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Suzhou Highfine Biotech Co Cash And Cash Equivalents?

Suzhou Highfine Biotech Co's quarterly cash and cash equivalents increased from Sep. 2024 (¥352.52 Mil) to Dec. 2024 (¥361.08 Mil) and increased from Dec. 2024 (¥361.08 Mil) to Mar. 2025 (¥551.51 Mil).

Suzhou Highfine Biotech Co's annual cash and cash equivalents increased from Dec. 2022 (¥99.32 Mil) to Dec. 2023 (¥1,739.51 Mil) but then declined from Dec. 2023 (¥1,739.51 Mil) to Dec. 2024 (¥361.08 Mil).

Suzhou Highfine Biotech Co Cash And Cash Equivalents Historical Data

The historical data trend for Suzhou Highfine Biotech Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Highfine Biotech Co Cash And Cash Equivalents Chart

Suzhou Highfine Biotech Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

92.07

99.32

1,739.51

361.08

Suzhou Highfine Biotech Co Quarterly Data
	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															1,734.90	929.43	352.52	361.08	551.51

Suzhou Highfine Biotech Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Suzhou Highfine Biotech Co (SZSE:301393) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Suzhou Highfine Biotech Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Suzhou Highfine Biotech Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Highfine Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suzhou Highfine Biotech Co Ltd (SZSE:301393) » Definitions » Cash And Cash Equivalents

Traded in Other Exchanges

N/A

Address

No. 32 Hongxi Road, F-12 Standard Factory Building, High-tech Zone, Jiangsu Province, Suzhou, CHN, 215151

Website

https://www.highfine.com

Suzhou Highfine Biotech Co Ltd is a high-tech enterprise that provides characteristic raw materials for global pharmaceutical research and development and raw material drug production companies. The products are mainly used in the fields of peptide, nucleotide and pharmaceutical synthesis. The product range covers peptide synthesis reagents for characteristic amide bond formation, molecular building blocks, protein reagents, liposome and lipid nanoparticle pharmaceutical reagents, ionic liquids , PROTAC reagents and nucleotide reagents and other types.

Executives

Dong Sheng Jun	Directors, executives
Lu Xue Gen	Directors, executives
Lv Min Jie	Directors, executives
Xu Jie	Directors, executives

Suzhou Highfine Biotech Co Headlines

No Headlines